333 related articles for article (PubMed ID: 33906872)
21. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
[TBL] [Abstract][Full Text] [Related]
22. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
[No Abstract] [Full Text] [Related]
23. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
Gleue CA; Shah K; Wentworth A; Bridges A
J Cutan Pathol; 2021 Mar; 48(3):425-428. PubMed ID: 33128468
[TBL] [Abstract][Full Text] [Related]
25. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
26. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract][Full Text] [Related]
27. Successful Alectinib Treatment for Carcinoma of Unknown Primary with
Sugiyama K; Izumika A; Iwakoshi A; Nishibori R; Sato M; Shiraishi K; Hattori H; Nishimura R; Kitagawa C
Curr Oncol; 2021 May; 28(3):1938-1945. PubMed ID: 34064158
[TBL] [Abstract][Full Text] [Related]
28. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
29. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
[TBL] [Abstract][Full Text] [Related]
30. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
31. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
32. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
[TBL] [Abstract][Full Text] [Related]
33. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
34. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
35. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract][Full Text] [Related]
36. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
37. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
38. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
39. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R; Filho SNM; Li M; Fares A; Weiss J; Pham NA; Ludkovski O; Raghavan V; Li Q; Ravi D; Cabanero M; Moghal N; Leighl NB; Bradbury P; Sacher A; Shepherd FA; Yasufuku K; Tsao MS; Liu G
Lung Cancer; 2020 Aug; 146():78-85. PubMed ID: 32521388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
